Founding AdvaMedDx Board Member and Bio-Rad President & CEO Norman Schwartz Named Chair of AdvaMedDx

You are here

Founding AdvaMedDx Board Member and Bio-Rad President & CEO Norman Schwartz Named Chair of AdvaMedDx

February 22, 2021

Outgoing Chair Doug Bryant praised for leadership through pandemic

WASHINGTON, D.C. – AdvaMedDx, the division within AdvaMed representing manufacturers of in vitro diagnostic tests, foundational to the delivery of quality health care, announced that Norman Schwartz, President & CEO of Bio-Rad Laboratories, Inc. and founding Board member of AdvaMedDx, has been named chair of the AdvaMedDx Board of Directors for a two-year term. 

Schwartz became president and CEO of Bio-Rad in 2003 and was later named Chairman of the Board in 2012. Previously, he led both the Clinical Diagnostics Group and the Life Science Group and held other positions at the company as well. Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets serving university and research institutions; hospitals; public health and commercial laboratories; and biotechnology, pharmaceutical, and applied research laboratories that include food safety and environmental quality testing.

“Diagnostics technologies have always played a major role in the global health care system,” Schwartz said. “Over the course of the last year, since the onset of the COVID-19 pandemic, that role has assumed an entirely new significance. Diagnostics companies innovated nearly overnight to deliver the diagnostic tools that are helping communities direct proper treatment for their patients, track and slow the spread of disease, and protect people at work and in schools. I am grateful for the opportunity to lead AdvaMedDx at such a critical time, reiterating the commitment of this industry to fully support our nation’s COVID-19 response with innovative and varied products. Our work will focus more broadly on striving to achieve modernizations to the regulatory apparatus to unleash greater innovation, allowing quality tests to reach patients and providers sooner,” he said.

“Norman has remarkable insight into the life science and clinical diagnostics fields, with an eye to supporting innovation to advance the health and health care of patients and the public,” said Susan Van Meter, executive director of AdvaMedDx. “He knows both this industry and the association inside and out. I have full confidence under Norman’s leadership we will meaningfully expand our efforts to highlight the value of diagnostics and smart diagnostics policy around the world.”

Schwartz succeeds Doug Bryant, President & CEO of Quidel Corporation, who has served as chair of AdvaMedDx since 2018. Bryant has led the industry association through the most significant time in its history, when the demand for quality diagnostic and serology tests was unprecedented, given the essential role testing has served and continues to serve in the national and global response to the COVID-19 pandemic. 

“Doug’s leadership has been steadfast and tireless throughout his chairmanship, and particularly during this last year,” said Van Meter. "He has helped make sure policymakers understand that in order to extend the reach of quality COVID-19 testing, all molecular, antigen, and serology/antibody tests for all appropriate use cases need to be fully leveraged across both laboratory-based and point-of-care modalities. I know I speak for the entire organization when I say that we are grateful to Doug for the excellence he has brought to leading AdvaMedDx over the past three years.” 

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit

AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad. For more information, click here.